VTRS

Viatris Inc

18.65

Oct 20 • 3:59 PM ET +0.39 (2.14%)

18.64

Aftermarket • 7:30 PM ET -0.01 (-0.05%)

Healthcare Drug Manufacturers - Specialty & Generic USA Large NASD

Peers: TEVA AMRX RDY OGN ANIP BHC TAK PRGO ALVO PFE

| Held by: VTI VOO VB VBR IVV SPY RSP XLV IWR VYM

Scroll to Statements

Index	S&P 500
Market Cap	21.42B
Enterprise Value	33.64B
Income	-410.70M
Sales	14.75B
Book/sh	12.34
Cash/sh	1.23
Dividend Est.	0.52 (2.78%)
Dividend TTM	0.48 (2.57%)
Dividend Ex-Date	Aug 21, 2026
Dividend Gr. 3/5Y	0.00% -
Payout	-
Employees	30000
IPO	Mar 17, 1980

P/E	-
Forward P/E	6.94
PEG	1.00
P/S	1.45
P/B	1.51
P/C	15.19
P/FCF	10.96
EV/EBITDA	7.95
EV/Sales	2.28
Quick Ratio	0.87
Current Ratio	1.49
Debt/Eq	0.96
LT Debt/Eq	0.83
Option/Short	Yes / Yes

EPS (ttm)	-0.36
EPS next Y	2.69
EPS next Q	0.64
EPS this Y	7.21%
EPS next Y	6.69%
EPS next 5Y	6.91%
EPS past 3/5Y	- -21.93%
Sales past 3/5Y	-4.04% 3.66%
EPS Y/Y TTM	87.81%
Sales Y/Y TTM	4.92%
EPS Q/Q	-2517.95%
Sales Q/Q	5.05%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	14.79% 2.21%

Insider Own	2.07%
Insider Trans	-0.21%
Inst Own	93.12%
Inst Trans	-0.08%
ROA	-1.12%
ROE	-2.75%
ROIC	-1.58%
Gross Margin	39.58%
Oper. Margin	9.69%
Profit Margin	-2.78%
SMA20	4.99%
SMA50	9.31%
SMA200	19.10%
Trades

Shs Outstand	1.16B
Shs Float	1.12B
Short Float	3.74%
Short Ratio	4.52
Short Interest	42.04M
52W High	18.75 -0.53%
52W Low	9.92 88.00%
Volatility	3.01% 2.88%
ATR (14)	0.49
RSI (14)	65.45
Beta	0.89
Rel Volume	1.54
Avg Volume	9.29M
Volume	14,265,922

Perf Week	8.12%
Perf Month	9.06%
Perf Quarter	9.64%
Perf Half Y	26.61%
Perf YTD	49.80%
Perf Year	80.89%
Perf 3Y	100.54%
Perf 5Y	33.31%
Perf 10Y	-50.41%
Recom	2.21
Target Price	20.00
Prev Close	18.26
Price	18.65
Change %	2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Initiated	Oppenheimer	Outperform	$25
Sep-09-26	Initiated	Leerink Partners	Outperform	$20
Feb-09-26	Upgrade	UBS	Neutral → Buy	$18
Jan-16-26	Upgrade	Argus	Hold → Buy	$15
Dec-09-25	Initiated	Barclays	Overweight	$15
Oct-15-25	Initiated	Truist	Buy	$15
Jun-06-25	Initiated	Goldman	Neutral	$10
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13

Show Previous Ratings

Oct-19-26 06:44AM	FDA approves Viatris' Ryzumvi for adult presbyopia (Pharmaceutical Business Review)
Oct-16-26 04:05PM	Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia (PR Newswire)
01:58PM	Opus Genetics Secures FDA Approval For Eye Drops Set To Receive Milestone Payment (Stocktwits)
Oct-12-26 02:32AM	Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Colas Costa Coffee Sale, Devons Eagle Ford Divestiture In Focus (Stocktwits)
Oct-09-26 09:12PM	Stocktwits Biotech Dealmaker Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights (Stocktwits)
04:22PM	Loading…
Oct-08-26 04:22PM	Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly (Investor's Business Daily)
02:31PM	Viatris to acquire Pacira BioSciences for $1.65 billion (Quartz)
01:48PM	HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff Whats Driving The Momentum Today? (Stocktwits)
01:20PM	Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout (Pharmaceutical Technology)
12:01PM	Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition (Barrons.com)
12:00PM	Viatris boosts pain drug portfolio with $1.7B buyout of Pacira (BioPharma Dive)
10:37AM	Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion (InvestorsHub)
08:48AM	Viatris to Buy Pacira BioSciences for $1.65 Billion (The Wall Street Journal)
07:45AM	Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies (PR Newswire)
Oct-05-26 07:21AM	FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application (Stocktwits)
06:59AM	Loading…
06:59AM	Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 (PR Newswire)
Sep-29-26 02:00PM	Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year (PR Newswire)
Sep-25-26 03:53PM	Viatris sues Novo Nordisk over generic Wegovy patent dispute (Investing.com)
Sep-16-26 09:46AM	Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation (InvestorsHub)
06:59AM	Viatris Announces Approval of WAKIX (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome (PR Newswire)
Aug-28-26 05:15AM	Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris (Proactive)
Aug-25-26 04:41PM	The Real Engine That Could Power Tesla Stock Higher (Trefis)
04:20PM	Dell Stock's Massive Guidance Raise Has A Catch (Trefis)
Aug-06-26 07:14PM	Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ... (GuruFocus.com) -7.71%
04:30PM	Viatris Inc. stock falls Thursday, underperforms market (MarketWatch)
07:18AM	Viatris: Q2 Earnings Snapshot (Associated Press)
06:59AM	Viatris Reports Second-Quarter 2026 Financial Results (PR Newswire)
Aug-04-26 06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
Jul-29-26 06:59AM	Viatris Receives U.S. FDA Approval for Gwyn Lo, a Once-Weekly Contraceptive Patch (PR Newswire)
Jul-22-26 03:56PM	Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2% (GuruFocus.com)
06:59AM	Loading…
Jul-01-26 06:59AM	Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 (PR Newswire)
Jun-29-26 06:59AM	Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy (PR Newswire)
May-18-26 08:00AM	U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain (PR Newswire)
May-07-26 08:26PM	Viatris Inc. Q1 2026 Earnings Call Summary (Moby) +9.03%
04:30PM	Viatris to Present at the Bank of America Securities 2026 Healthcare Conference (PR Newswire)
04:30PM	Viatris Inc. stock rises Thursday, outperforms market (MarketWatch)
07:06AM	Viatris: Q1 Earnings Snapshot (Associated Press)
06:59AM	Viatris Reports First-Quarter 2026 Financial Results (PR Newswire)
May-05-26 06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
05:36AM	Edwards names Theodora Mistras as CFO (MedTech Dive)
May-04-26 04:30PM	Viatris Announces Chief Financial Officer Transition (PR Newswire)
Apr-13-26 06:59AM	Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 (PR Newswire)
Apr-10-26 06:59AM	Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting (PR Newswire)
Mar-28-26 10:04AM	Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight (GuruFocus.com)
Mar-23-26 06:59AM	Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) (PR Newswire)
Mar-19-26 08:30AM	Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 (PR Newswire)
Mar-10-26 12:02AM	Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-04-26 09:40AM	Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-03-26 05:25AM	Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value (Insider Monkey) -5.16%
Mar-02-26 10:34PM	Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 (StockStory) +5.16%
Feb-28-26 12:40PM	UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve (Insider Monkey)
Feb-27-26 07:02AM	Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date (Insider Monkey)
Feb-26-26 04:08PM	Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives (GuruFocus.com) -5.16%
02:24PM	Analyst Report: Viatris Inc. (Morningstar Research)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
10:00AM	Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:55AM	Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
08:37AM	Viatris forecasts 2026 profit below estimates on India manufacturing woes (Reuters)
07:27AM	Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 (StockStory)
07:10AM	Viatris: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results (PR Newswire)
06:55AM	Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend (PR Newswire)
Feb-25-26 06:59AM	FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia (PR Newswire)
Feb-24-26 10:24PM	Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow (StockStory)
08:02AM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
Feb-23-26 09:15AM	Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-19-26 10:00AM	Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 03:54AM	UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade (Insider Monkey)
Feb-10-26 06:41AM	Where is Viatris Inc. (VTRS) Headed According to the Street? (Insider Monkey)
Feb-09-26 04:34PM	Stocks Settle Higher on Strength in Tech (Barchart) +6.72%
03:31PM	Why Viatris (VTRS) Stock Is Up Today (StockStory)
Feb-06-26 07:00PM	Women Are One Patch Away From Menopause Reliefif Only They Could Find It (The Wall Street Journal)
Feb-03-26 04:34PM	Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 (PR Newswire)
08:30AM	Viatris Appoints Matthew J. Maletta as Chief Legal Officer (PR Newswire)
Feb-02-26 08:42AM	What Are Wall Street Analysts' Target Price for Viatris Stock? (Barchart)
Jan-22-26 06:33AM	Viatris Earnings Preview: What to Expect (Barchart)
Jan-21-26 11:02PM	3 Reasons to Sell VTRS and 1 Stock to Buy Instead (StockStory)
Jan-20-26 06:59AM	Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure (PR Newswire)
Jan-08-26 09:05AM	Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer (PR Newswire)
Jan-06-26 12:00PM	Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-02-26 09:44AM	Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones (Insider Monkey)
Dec-30-25 05:38PM	Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves (Insider Monkey)
Dec-19-25 12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
Dec-18-25 06:59AM	Viatris Provides Pipeline Update on Four Regulatory Milestones (PR Newswire)
Dec-17-25 06:59AM	Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-15-25 10:33AM	Is Viatris Stock Outperforming the Dow? (Barchart)
Dec-08-25 05:17AM	Viatris signs agreements with Biocon on $815m stake sale (Pharmaceutical Business Review)
Dec-06-25 09:00AM	Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited (PR Newswire)
Dec-04-25 02:08PM	Mark Cuban Takes Aim at FDA Fees (GuruFocus.com)
Nov-24-25 08:00AM	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-19-25 03:00AM	European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe (PR Newswire)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
Nov-13-25 08:00AM	Viatris Recognized as One of the Fortune World's Best Workplaces in 2025 (PR Newswire)
Nov-12-25 10:36PM	Reflecting On Generic Pharmaceuticals Stocks' Q3 Earnings: Viatris (NASDAQ:VTRS) (StockStory)
07:00AM	Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets (Insider Monkey)
Nov-11-25 07:47PM	Analyst Report: Viatris Inc. (Morningstar Research) +10.13%
03:55PM	Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know (StockStory)
10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Enrietti Andrew	See Remarks	Aug 15 '26	Option Exercise	0.00	26,133	0	244,811	Aug 18 06:01 PM
Campbell Paul	See Remarks	Jun 25 '26	Sale	16.17	50,076	809,784	316,212	Jun 26 05:00 PM
Paul Campbell	Officer	Jun 25 '26	Proposed Sale	16.17	50,076	809,678		Jun 25 04:27 PM
Le Goff Corinne	Chief Commercial Officer	Apr 15 '26	Option Exercise	0.00	42,988	0	122,558	Apr 16 06:00 PM
Campbell Paul	See Remarks	Mar 23 '26	Sale	13.28	21,350	283,539	366,288	Mar 24 06:04 PM
Paul Campbell	Officer	Mar 23 '26	Proposed Sale	13.28	21,350	283,508		Mar 23 04:49 PM
Le Goff Corinne	Chief Commercial Officer	Mar 06 '26	Option Exercise	0.00	46,358	0	101,582	Mar 10 07:04 PM
Mistras Theodora	Chief Financial Officer	Mar 06 '26	Option Exercise	0.00	43,782	0	92,787	Mar 10 07:04 PM
SEVERINO MICHAEL	Director	Mar 06 '26	Option Exercise	0.00	26,031	0	26,031	Mar 10 07:03 PM
PARRISH MARK W	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	165,230	Mar 10 07:03 PM
MARK RICHARD A	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	116,145	Mar 10 07:03 PM
Campbell Paul	See Remarks	Mar 06 '26	Option Exercise	0.00	28,974	0	398,956	Mar 10 07:03 PM
Smith Scott Andrew	Chief Executive Officer	Mar 06 '26	Option Exercise	0.00	130,701	0	1,374,576	Mar 10 07:03 PM
HIGGINS MELINA E	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	146,048	Mar 10 07:03 PM
Groothuis Leo Frans	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	63,567	Mar 10 07:03 PM
SIMMONS DAVID S	Director	Mar 06 '26	Option Exercise	0.00	23,344	0	23,344	Mar 10 07:03 PM
SIMMONS DAVID S	Director	Nov 03 '25	Buy	10.43	213	2,221	1,183	Mar 10 07:03 PM
Lyons Dillon JoEllen	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	102,526	Mar 10 07:03 PM
KILTS JAMES M	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	161,257	Mar 10 07:03 PM
Vivaldi Coelho Rogerio	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	46,526	Mar 10 07:03 PM
DAMELIO FRANK A	Director	Mar 06 '26	Option Exercise	0.00	26,031	0	26,031	Mar 10 07:03 PM
CORNWELL W DON	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	112,044	Mar 10 07:03 PM
FINNEY ELISHA W	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	62,667	Mar 10 07:03 PM
Mistras Theodora	Chief Financial Officer	Mar 04 '26	Option Exercise	0.00	34,084	0	66,991	Mar 05 07:00 PM
Le Goff Corinne	Chief Commercial Officer	Mar 04 '26	Option Exercise	0.00	39,773	0	72,019	Mar 05 07:00 PM
Enrietti Andrew	See Remarks	Mar 03 '26	Option Exercise	0.00	110,630	0	248,032	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 04 '26	Option Exercise	0.00	18,720	0	377,939	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 03 '26	Option Exercise	0.00	190,027	0	435,151	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 04 '26	Option Exercise	0.00	101,217	0	1,281,172	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '26	Option Exercise	0.00	1,440,831	0	1,695,045	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	25,260	0	48,265	Jan 02 06:00 PM

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

CEO & DirectorMr. Scott Andrew Smith Ph.D.

Chief Administrative & Transformation OfficerMr. Andrew Enrietti

Pharm.D.Dr. Corinne M. Le Goff M.B.A.

Interim CFOMr. Paul B. Campbell

Chief Information OfficerMr. Ramkumar V. Rayapureddy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTRS

Viatris Inc

Upgrade your Finviz experience